The latest price target for Veracyte (NASDAQ:VCYT) was reported by Morgan Stanley on November 18, 2024. The analyst firm set a price target for $28.00 expecting VCYT to fall to within 12 months (a possible -29.28% downside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by Morgan Stanley, and Veracyte maintained their underweight rating.

There is no last upgrade for Veracyte

The last downgrade for Veracyte Inc happened on January 18, 2023 when Raymond James changed their price target from N/A to N/A for Veracyte Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $26.00 to $28.00. The current price Veracyte (VCYT) is trading at is $39.59, which is out of the analyst’s predicted range.